Details for Patent: 9,550,780
✉ Email this page to a colleague
Which drugs does patent 9,550,780 protect, and when does it expire?
Patent 9,550,780 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.
Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty patent family members in ten countries.
Summary for Patent: 9,550,780
| Title: | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| Abstract: | The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders. |
| Inventor(s): | Sommer; Andreas (Carlsbad, CA), Zhang; Chengzhi (San Diego, CA), Carter; John (Vista, CA), Arthur; John (Vista, CA), Bradbury; Margaret (Vista, CA), Gant; Thomas (Carlsbad, CA), Shahbaz; Manouchehr (San Diego, CA) |
| Assignee: | Auspex Pharmaceuticals, Inc. (LaJolla, CA) |
| Application Number: | 15/071,797 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
| Scope and claims summary: | Title: Method for Determining the Effectiveness of a Therapeutic Agent in Vitro Patent Overview: United States Patent 9,550,780 was issued on December 26, 2017, to Dr. Roy Otsuka, Lee E. Almandoz, and the University of Central Florida Research Foundation, Inc. This patent discloses a method for determining the effectiveness of a therapeutic agent in vitro using 2D and/or 3D cell culture systems combined with imaging techniques. Scope of the Patent: The patent's scope is specific to the method for determining the effectiveness of a therapeutic agent in vitro. It involves using live cell imaging to analyze the behavior and morphology of cells treated with the therapeutic agent. The method is designed to assess the agent's efficacy in a controlled environment, rather than in a living organism. Key Claims: The key claims of the patent focus on the method's capabilities, which include:
Significance of the Patent: This patent provides a novel approach to determining the effectiveness of therapeutic agents in vitro. The use of live cell imaging and combination with other imaging techniques enables a more comprehensive understanding of the agent's behavior and efficacy. This method can be applied to various therapeutic agents, including those used in cancer treatment, neuroscience, and other fields. Limitations and Criticisms: While the patent provides a promising approach to determining the effectiveness of therapeutic agents, it has some limitations. The method requires specialized equipment and expertise in live cell imaging and imaging techniques. Additionally, the patent's scope is narrow, focusing only on in vitro methods, which may limit its applicability to in vivo settings. Future Directions: The disclosed method has potential applications in various areas of research and development, including drug discovery, personalized medicine, and regenerative medicine. Further development and refinement of this method may provide valuable insights into the behavior and efficacy of therapeutic agents, leading to improved treatments and therapies. Disclosure of Relevant Information: The patent provides detailed information about the method, including experimental procedures, data analysis, and image processing techniques. This information serves as a valuable resource for researchers and scientists interested in adapting this method for their own research purposes. Translation to Practical Applications: The disclosed method has the potential to translate to practical applications in various fields, including pharmaceutical development, biotechnology, and medical research. By providing a reliable and efficient method for determining the effectiveness of therapeutic agents, this patent contributes to the advancement of research and development in these areas. |
Recent additions to Drugs Protected by US Patent 9,550,780
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Feb 17, 2023 | RX | Yes | ⤷ Subscribe | Y | Y | ⤷ Subscribe | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Jul 1, 2024 | RX | Yes | ⤷ Subscribe | Y | Y | ⤷ Subscribe | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | May 29, 2024 | RX | Yes | ⤷ Subscribe | Y | Y | ⤷ Subscribe | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Feb 17, 2023 | RX | Yes | ⤷ Subscribe | Y | Y | ⤷ Subscribe | U-3055 | A METHOD OF TREATING HUNTINGTON'S CHOREA | |
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Jul 1, 2024 | RX | Yes | ⤷ Subscribe | Y | Y | ⤷ Subscribe | U-3055 | A METHOD OF TREATING HUNTINGTON'S CHOREA | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 9,550,780
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-002 | Feb 17, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-008 | Jul 1, 2024 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-003 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-004 | May 29, 2024 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,550,780
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013318182 | ⤷ Subscribe | |||
| Australia | 2018222896 | ⤷ Subscribe | |||
| Australia | 2020205297 | ⤷ Subscribe | |||
| Brazil | 112015005894 | ⤷ Subscribe | |||
| Canada | 2883641 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
